AU2022364646B2 - SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF - Google Patents

SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF

Info

Publication number
AU2022364646B2
AU2022364646B2 AU2022364646A AU2022364646A AU2022364646B2 AU 2022364646 B2 AU2022364646 B2 AU 2022364646B2 AU 2022364646 A AU2022364646 A AU 2022364646A AU 2022364646 A AU2022364646 A AU 2022364646A AU 2022364646 B2 AU2022364646 B2 AU 2022364646B2
Authority
AU
Australia
Prior art keywords
pyrazolo
methoxy
quinolin
dimethylphenyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022364646A
Other languages
English (en)
Other versions
AU2022364646A1 (en
Inventor
Ruben Abagyan
Alexandre Vasilievich IVACHTCHENKO
Oleg MITKIN
Vladislav Zenonovich Parchinsky
Alexei Pushechnikov
Nikolay Savchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lomond Therapeutics Inc
Original Assignee
Lomond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lomond Therapeutics Inc filed Critical Lomond Therapeutics Inc
Publication of AU2022364646A1 publication Critical patent/AU2022364646A1/en
Application granted granted Critical
Publication of AU2022364646B2 publication Critical patent/AU2022364646B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022364646A 2021-10-15 2022-10-03 SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF Active AU2022364646B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256260P 2021-10-15 2021-10-15
US63/256,260 2021-10-15
PCT/US2022/045555 WO2023064133A1 (en) 2021-10-15 2022-10-03 SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF

Publications (2)

Publication Number Publication Date
AU2022364646A1 AU2022364646A1 (en) 2024-03-28
AU2022364646B2 true AU2022364646B2 (en) 2025-10-09

Family

ID=85988576

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022364646A Active AU2022364646B2 (en) 2021-10-15 2022-10-03 SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF

Country Status (11)

Country Link
US (1) US20250011319A1 (enExample)
EP (1) EP4416146A4 (enExample)
JP (1) JP2024539633A (enExample)
KR (1) KR20240093606A (enExample)
CN (1) CN118076605A (enExample)
AU (1) AU2022364646B2 (enExample)
CA (1) CA3233233A1 (enExample)
MX (1) MX2024004569A (enExample)
TW (2) TWI863003B (enExample)
WO (1) WO2023064133A1 (enExample)
ZA (1) ZA202406375B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118666857B (zh) * 2024-06-26 2025-02-25 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080729A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
MA42456B1 (fr) * 2015-06-25 2021-06-30 Univ Health Network Inhibiteurs de hpk1 et leurs procédés d'utilisation
US12486264B2 (en) * 2019-03-26 2025-12-02 Janssen Pharmaceutica Nv Bicyclic HPK1 inhibitors
US20210269434A1 (en) * 2020-01-10 2021-09-02 Incyte Corporation Tricyclic compounds as inhibitors of kras
AU2021254794A1 (en) * 2020-04-16 2022-12-15 Incyte Corporation Fused tricyclic KRAS inhibitors

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 901030-72-6; STN Entry Date 14 August 2006; 3-(4-ethoxyphenyl)-8-fluoro-1-(4-fluorophenyl)-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901030-76-0; STN Entry Date 14 August 2006; 3-(4-ethoxyphenyl)-8-fluoro-1-phenyl-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901030-78-2; STN Entry Date 14 August 2006; 3-(4-ethoxyphenyl)-8-ethyl-1-phenyl-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901030-80-6; STN Entry Date 14 August 2006; 1-(3,4-dimethylphenyl)-3-(4-ethoxyphenyl)-6,8-difluoro-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901030-82-8; STN Entry Date 14 August 2006; 1-(4-chlorophenyl)-3-(4-ethoxyphenyl)-8-methyl-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901030-84-0; STN Entry Date 14 August 2006; 3-(4-ethoxyphenyl)-1-(4-fluorophenyl)-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901030-86-2; STN Entry Date 14 August 2006; 1-(4-chlorophenyl)-3-(4-ethoxyphenyl)-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901030-90-8; STN Entry Date 14 August 2006; 1-(4-chlorophenyl)-3-(4-ethoxyphenyl)-6,8-difluoro-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901229-09-2 ; STN Entry Date 14 August 2006; 1-(3,4-dimethylphenyl)-3-(4-ethoxyphenyl)-8-fluoro-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901229-15-0 ; STN Entry Date 14 August 2006; 1-(4-chlorophenyl)-3-(4-ethoxyphenyl)-8-fluoro-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901229-21-8; STN Entry Date 14 August 2006; 3-(4-ethoxyphenyl)-8-fluoro-1-(4-methylphenyl)-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901229-27-4; STN Entry Date 14 August 2006; 3-(4-ethoxyphenyl)-8-methyl-1-phenyl-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901229-32-1; STN Entry Date 14 August 2006; 3-(4-ethoxyphenyl)-6,8-difluoro-1-phenyl-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901229-38-7; STN Entry Date 14 August 2006; 3-(4-ethoxyphenyl)-1-(4-fluorophenyl)-8-methyl-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901229-53-6; STN Entry Date 14 August 2006; 1-(4-chlorophenyl)-3-(4-ethoxyphenyl)-8-ethyl-1H-Pyrazolo[4,3-c]quinoline *
CAS Registry Number 901229-60-5; STN Entry Date 14 August 2006; 3-(4-Ethoxyphenyl)-8-ethyl-1-(4-methylphenyl)-1H-pyrazolo[4,3-c]quinoline *
CAS Registry Number 901229-71-8; STN Entry Date 14 August 2006; 3-(4-ethoxyphenyl)-6,8-difluoro-1-(4-fluorophenyl)- 1H-Pyrazolo[4,3-c]quinoline *

Also Published As

Publication number Publication date
EP4416146A1 (en) 2024-08-21
ZA202406375B (en) 2025-01-29
CA3233233A1 (en) 2023-04-20
AU2022364646A1 (en) 2024-03-28
CN118076605A (zh) 2024-05-24
JP2024539633A (ja) 2024-10-29
TW202317567A (zh) 2023-05-01
TWI863003B (zh) 2024-11-21
TW202442645A (zh) 2024-11-01
MX2024004569A (es) 2024-04-30
US20250011319A1 (en) 2025-01-09
WO2023064133A1 (en) 2023-04-20
EP4416146A4 (en) 2025-11-05
KR20240093606A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
US9605005B2 (en) Alkynyl alcohols and methods of use
KR101959590B1 (ko) c-KIT 키나제 억제제로서의 화합물 및 조성물
JP2024020220A (ja) 免疫調節剤としての複素環式化合物
US20240208912A1 (en) MTA-Cooperative PRMT5 Inhibitors
AU2007248603B2 (en) Pyrido [2, 3-b] pyrazine and [1, 8] -naphthyridine derivatives as ALK and c-Met inhibitors
CA2663401C (en) Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
WO2024046370A1 (zh) 作为kras抑制剂的杂环化合物，及其制备和治疗用途
JP7547387B2 (ja) ＮＦ－κＢ誘導キナーゼの低分子阻害剤
CN105814047A (zh) 作为tnf活性调节剂的稠合三环咪唑衍生物
JP2016531127A (ja) アルキニルアルコール及び使用方法
EA036679B1 (ru) Замещенные соединения тетрагидрохинолинона в качестве ингибиторов ретиноидных орфановых рецепторов гамма (ror)
JP6582056B2 (ja) Ｃｘｃｒ７受容体調節剤
KR20180052702A (ko) Perk 억제제로서의 1-페닐피롤리딘-2-온 유도체
KR20170075756A (ko) 카르바졸 유도체
CA3202212A1 (en) Indole derivatives useful in treating conditions associated with cgas
TW202220993A (zh) Atr抑制劑及其用途
KR102563829B1 (ko) 거대고리 rip2 키나아제 억제제
AU2022364646B2 (en) SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
AU2024333590A1 (en) Compounds and compositions as cbp/p300 degraders and uses thereof
CN116437918A (zh) 作为tam抑制剂的吡唑并吡啶化合物
EP4416151A1 (en) Chimeric compounds useful in treating diseases
KR20160045817A (ko) 알킨일 알콜 및 사용 방법
HK1225377A1 (en) Alkynyl alcohols and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)